Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.

Onglets principaux

Velghe, Amélie [UCL] Van Cauwenberghe, S Polyansky, A A Chand, D Montano-Almendras, C P Essaghir, Ahmed [UCL] Demoulin, Jean-Baptiste [UCL]

Activating mutations in the platelet-derived growth factor (PDGF) receptor alpha (PDGFRA) have been described in patients with gastrointestinal stromal tumors or myeloid malignancies associated with hypereosinophilia. These patients respond well to imatinib mesylate, raising the question as to whether patients with a PDGF receptor mutation in other tumor types should receive a tyrosine kinase inhibitor treatment. We characterized 10 novel somatic point mutations in PDGFRA that have been reported in isolated cases of glioblastoma, melanoma, acute myeloid leukemia, peripheral nerve sheath tumors and neuroendocrine carcinoma. The PDGFRA transmembrane domain mutation V536E stimulated Ba/F3 cell growth and signaling via ERK and STAT5 in the absence of ligand. This mutant, identified in glioblastoma, was strongly inhibited by imatinib. Modeling suggested that the mutation modulates the packing of the transmembrane domain helices in the receptor dimer. By contrast, two mutations in highly conserved residues affected the receptor traffic to the cell surface or kinase activity, thereby preventing the response to PDGF. The other mutations had no significant impact on the receptor activity. This functional analysis matched the predictions of SIFT and PolyPhen for only five mutations and these algorithms do not discriminate gain from loss of function. Finally, an E996K variant that had been identified in a melanoma cell line was not expressed in these cells. Altogether, several newly identified PDGFRA mutations do not activate the receptor and may therefore represent passenger mutations. Our results also underline the importance of characterizing novel kinase alterations in cancer patients.Oncogene advance online publication, 10 June 2013; doi:10.1038/onc.2013.218.

Type de document Article de périodique (Journal article) – Article de recherche
Année de publication 2014
Langue Anglais
Information sur le périodique "Oncogene" - Vol. 33, no. 20, p. 2568-76 (2014)
Peer reviewed oui
Editeur Nature Publishing Group ((United Kingdom) London)
issn 0950-9232
e-issn 1476-5594
Statut de la publication Publié
Affiliations UCL - SSS/DDUV - Institut de Duve
Liens
  1. Andrae J., Gallini R., Betsholtz C., Role of platelet-derived growth factors in physiology and medicine, 10.1101/gad.1653708
  2. Chiara Federica, Bishayee Subal, Heldin Carl-Henrik, Demoulin Jean-Baptiste, Autoinhibition of the Platelet-derived Growth Factor β-Receptor Tyrosine Kinase by Its C-terminal Tail, 10.1074/jbc.m314070200
  3. Toffalini F., Demoulin J.-B., New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases, 10.1182/blood-2010-04-279752
  4. Corless Christopher L., Schroeder Arin, Griffith Diana, Town Ajia, McGreevey Laura, Harrell Patina, Shiraga Sharon, Bainbridge Troy, Morich Jason, Heinrich Michael C., PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib, 10.1200/jco.2005.14.068
  5. Demoulin JB, Am J Blood Res, 2, 44 (2012)
  6. Medves Sandrine, Demoulin Jean-Baptiste, Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies, 10.1111/j.1582-4934.2011.01415.x
  7. Cools Jan, DeAngelo Daniel J., Gotlib Jason, Stover Elizabeth H., Legare Robert D., Cortes Jorges, Kutok Jeffrey, Clark Jennifer, Galinsky Ilene, Griffin James D., Cross Nicholas C.P., Tefferi Ayalew, Malone James, Alam Rafeul, Schrier Stanley L., Schmid Janet, Rose Michal, Vandenberghe Peter, Verhoef Gregor, Boogaerts Marc, Wlodarska Iwona, Kantarjian Hagop, Marynen Peter, Coutre Steven E., Stone Richard, Gilliland D. Gary, A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome, 10.1056/nejmoa025217
  8. Elling C., Erben P., Walz C., Frickenhaus M., Schemionek M., Stehling M., Serve H., Cross N. C. P., Hochhaus A., Hofmann W.-K., Berdel W. E., Muller-Tidow C., Reiter A., Koschmieder S., Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease, 10.1182/blood-2010-05-286757
  9. Huss Sebastian, Wardelmann Eva, Goltz Diane, Binot Elke, Hartmann Wolfgang, Merkelbach-Bruse Sabine, Büttner Reinhard, Schildhaus Hans-Ulrich, Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization : PDGFRA mutations in IFP, 10.1111/j.1365-2559.2012.04203.x
  10. Verhaak Roel G.W., Hoadley Katherine A., Purdom Elizabeth, Wang Victoria, Qi Yuan, Wilkerson Matthew D., Miller C. Ryan, Ding Li, Golub Todd, Mesirov Jill P., Alexe Gabriele, Lawrence Michael, O'Kelly Michael, Tamayo Pablo, Weir Barbara A., Gabriel Stacey, Winckler Wendy, Gupta Supriya, Jakkula Lakshmi, Feiler Heidi S., Hodgson J. Graeme, James C. David, Sarkaria Jann N., Brennan Cameron, Kahn Ari, Spellman Paul T., Wilson Richard K., Speed Terence P., Gray Joe W., Meyerson Matthew, Getz Gad, Perou Charles M., Hayes D. Neil, Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1, 10.1016/j.ccr.2009.12.020
  11. Clarke I D, Dirks P B, A human brain tumor-derived PDGFR-α deletion mutant is transforming, 10.1038/sj.onc.1206160
  12. Ozawa T., Brennan C. W., Wang L., Squatrito M., Sasayama T., Nakada M., Huse J. T., Pedraza A., Utsuki S., Yasui Y., Tandon A., Fomchenko E. I., Oka H., Levine R. L., Fujii K., Ladanyi M., Holland E. C., PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas, 10.1101/gad.1972310
  13. David M., Cross N. C. P., Burgstaller S., Chase A., Curtis C., Dang R., Gardembas M., Goldman J. M., Grand F., Hughes G., Huguet F., Lavender L., McArthur G. A., Mahon F. X., Massimini G., Melo J., Rousselot P., Russell-Jones R. J., Seymour J. F., Smith G., Stark A., Waghorn K., Nikolova Z., Apperley J. F., Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders, 10.1182/blood-2006-05-024828
  14. Metzgeroth Georgia, Walz Christoph, Erben Philipp, Popp Helena, Schmitt-Graeff Annette, Haferlach Claudia, Fabarius Alice, Schnittger Susanne, Grimwade David, Cross Nicholas C. P., Hehlmann Rüdiger, Hochhaus Andreas, Reiter Andreas, Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study, 10.1111/j.1365-2141.2008.07294.x
  15. Paulsson Janna, Lindh Maja Bradic, Jarvius Malin, Puputti Marjut, Nistér Monica, Nupponen Nina N., Paulus Werner, Söderberg Ola, Dresemann Gregor, von Deimling Andreas, Joensuu Heikki, Östman Arne, Hasselblatt Martin, Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma, 10.1002/ijc.25528
  16. Dresemann Gregor, Weller Michael, Rosenthal Mark A., Wedding Ulrich, Wagner Wolfgang, Engel Erik, Heinrich Bernhard, Mayer-Steinacker Regine, Karup-Hansen Anders, Fluge Øystein, Nowak Anna, Mehdorn Maximilian, Schleyer Eberhard, Krex Dietmar, Olver Ian N., Steinbach Joachim P., Hosius Christian, Sieder Christian, Sorenson Greg, Parker Richard, Nikolova Zariana, Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide, 10.1007/s11060-009-9976-3
  17. Holtkamp N., Okuducu A. F., Mucha J., Afanasieva A., Hartmann C., Atallah I., Estevez-Schwarz L., Mawrin C., Friedrich R. E., Mautner V.-F., von Deimling A., Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity, 10.1093/carcin/bgi273
  18. Hiwatari M, Taki T, Tsuchida M, Hanada R, Hongo T, Sako M, Hayashi Y, Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor α(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22), 10.1038/sj.leu.2403638
  19. Greenman Christopher, Stephens Philip, Smith Raffaella, Dalgliesh Gillian L., Hunter Christopher, Bignell Graham, Davies Helen, Teague Jon, Butler Adam, Stevens Claire, Edkins Sarah, O’Meara Sarah, Vastrik Imre, Schmidt Esther E., Avis Tim, Barthorpe Syd, Bhamra Gurpreet, Buck Gemma, Choudhury Bhudipa, Clements Jody, Cole Jennifer, Dicks Ed, Forbes Simon, Gray Kris, Halliday Kelly, Harrison Rachel, Hills Katy, Hinton Jon, Jenkinson Andy, Jones David, Menzies Andy, Mironenko Tatiana, Perry Janet, Raine Keiran, Richardson Dave, Shepherd Rebecca, Small Alexandra, Tofts Calli, Varian Jennifer, Webb Tony, West Sofie, Widaa Sara, Yates Andy, Cahill Daniel P., Louis David N., Goldstraw Peter, Nicholson Andrew G., Brasseur Francis, Looijenga Leendert, Weber Barbara L., Chiew Yoke-Eng, deFazio Anna, Greaves Mel F., Green Anthony R., Campbell Peter, Birney Ewan, Easton Douglas F., Chenevix-Trench Georgia, Tan Min-Han, Khoo Sok Kean, Teh Bin Tean, Yuen Siu Tsan, Leung Suet Yi, Wooster Richard, Futreal P. Andrew, Stratton Michael R., Patterns of somatic mutation in human cancer genomes, 10.1038/nature05610
  20. Rand V., Huang J., Stockwell T., Ferriera S., Buzko O., Levy S., Busam D., Li K., Edwards J. B., Eberhart C., Murphy K. M., Tsiamouri A., Beeson K., Simpson A. J. G., Venter J. C., Riggins G. J., Strausberg R. L., Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas, 10.1073/pnas.0507200102
  21. Alentorn A., Marie Y., Carpentier C., Boisselier B., Giry M., Labussiere M., Mokhtari K., Hoang-Xuan K., Sanson M., Delattre J.-Y., Idbaih A., Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas, 10.1093/neuonc/nos217
  22. Toffalini Federica, Hellberg Carina, Demoulin Jean-Baptiste, Critical Role of the Platelet-derived Growth Factor Receptor (PDGFR) β Transmembrane Domain in the TEL-PDGFRβ Cytosolic Oncoprotein, 10.1074/jbc.m109.076638
  23. Keating MT, J Biol Chem, 264, 9129 (1989)
  24. Burke Christine L, Lemmon Mark A, Coren Barbara A, Engelman Donald M, Stern David F, Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation, 10.1038/sj.onc.1200873
  25. Yang Y., Yuzawa S., Schlessinger J., Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization, 10.1073/pnas.0802896105
  26. Polyansky Anton A., Volynsky Pavel E., Efremov Roman G., Multistate Organization of Transmembrane Helical Protein Dimers Governed by the Host Membrane, 10.1021/ja303483k
  27. Muhle-Goll Claudia, Hoffmann Silke, Afonin Sergii, Grage Stephan L., Polyansky Anton A., Windisch Dirk, Zeitler Marcel, Bürck Jochen, Ulrich Anne S., Hydrophobic Matching Controls the Tilt and Stability of the Dimeric Platelet-derived Growth Factor Receptor (PDGFR) β Transmembrane Segment, 10.1074/jbc.m111.325555
  28. Bell C. A., Tynan J. A., Hart K. C., Meyer A. N., Robertson S. C., Donoghue D. J., Rotational Coupling of the Transmembrane and Kinase Domains of the Neu Receptor Tyrosine Kinase, 10.1091/mbc.11.10.3589
  29. Arkhipov Anton, Shan Yibing, Das Rahul, Endres Nicholas F., Eastwood Michael P., Wemmer David E., Kuriyan John, Shaw David E., Architecture and Membrane Interactions of the EGF Receptor, 10.1016/j.cell.2012.12.030
  30. Endres Nicholas F., Das Rahul, Smith Adam W., Arkhipov Anton, Kovacs Erika, Huang Yongjian, Pelton Jeffrey G., Shan Yibing, Shaw David E., Wemmer David E., Groves Jay T., Kuriyan John, Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor, 10.1016/j.cell.2012.12.032
  31. Yuzawa Satoru, Opatowsky Yarden, Zhang Zhongtao, Mandiyan Valsan, Lax Irit, Schlessinger Joseph, Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor, 10.1016/j.cell.2007.05.055
  32. Omura Takashi, Heldin Carl-Henrik, Östman Arne, Immunoglobulin-like Domain 4-mediated Receptor-Receptor Interactions Contribute to Platelet-derived Growth Factor-induced Receptor Dimerization, 10.1074/jbc.272.19.12676
  33. Schönherr Christina, Ruuth Kristina, Eriksson Therese, Yamazaki Yasuo, Ottmann Christian, Combaret Valerie, Vigny Marc, Kamaraj Sattu, Palmer Ruth H., Hallberg Bengt, The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo, 10.1593/tlo.11139
  34. DEMOULIN Jean-Baptiste, SEO Jeong Kon, EKMAN Simon, GRAPENGIESSER Eva, HELLMAN Ulf, RÖNNSTRAND Lars, HELDIN Carl-Henrik, Ligand-induced recruitment of Na+/H+-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF, 10.1042/bj20030385
  35. Takahashi Yoko, Morales Fabiana C, Kreimann Erica L, Georgescu Maria-Magdalena, PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling, 10.1038/sj.emboj.7600979
  36. Fröhling Stefan, Scholl Claudia, Levine Ross L., Loriaux Marc, Boggon Titus J., Bernard Olivier A., Berger Roland, Döhner Hartmut, Döhner Konstanze, Ebert Benjamin L., Teckie Sewit, Golub Todd R., Jiang Jingrui, Schittenhelm Marcus M., Lee Benjamin H., Griffin James D., Stone Richard M., Heinrich Michael C., Deininger Michael W., Druker Brian J., Gilliland D. Gary, Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles, 10.1016/j.ccr.2007.11.005
  37. Ramensky V., Human non-synonymous SNPs: server and survey, 10.1093/nar/gkf493
  38. Zhang Jenny, Grubor Vladimir, Love Cassandra L., Banerjee Anjishnu, Richards Kristy L., Mieczkowski Piotr A., Dunphy Cherie, Choi William, Au Wing Yan, Srivastava Gopesh, Lugar Patricia L., Rizzieri David A., Lagoo Anand S., Bernal-Mizrachi Leon, Mann Karen P., Flowers Christopher, Naresh Kikkeri, Evens Andrew, Gordon Leo I., Czader Magdalena, Gill Javed I., Hsi Eric D., Liu Qingquan, Fan Alice, Walsh Katherine, Jima Dereje, Smith Lisa L., Johnson Amy J., Byrd John C., Luftig Micah A., Ni Ting, Zhu Jun, Chadburn Amy, Levy Shawn, Dunson David, Dave Sandeep S., Genetic heterogeneity of diffuse large B-cell lymphoma, 10.1073/pnas.1205299110
  39. Toffalini F., Kallin A., Vandenberghe P., Pierre P., Michaux L., Cools J., Demoulin J.-B., The fusion proteins TEL-PDGFR  and FIP1L1-PDGFR  escape ubiquitination and degradation, 10.3324/haematol.2008.001149
  40. Demoulin J B, Uyttenhove C, Van Roost E, DeLestré B, Donckers D, Van Snick J, Renauld J C, A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9., 10.1128/mcb.16.9.4710
  41. Montano-Almendras C. P., Essaghir A., Schoemans H., Varis I., Noel L. A., Velghe A. I., Latinne D., Knoops L., Demoulin J.-B., ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor- B, 10.3324/haematol.2011.047530
  42. Demoulin Jean-Baptiste, Ericsson Johan, Kallin Anders, Rorsman Charlotte, Rönnstrand Lars, Heldin Carl-Henrik, Platelet-derived Growth Factor Stimulates Membrane Lipid Synthesis Through Activation of Phosphatidylinositol 3-Kinase and Sterol Regulatory Element-binding Proteins, 10.1074/jbc.m405924200
  43. Schönherr C, Ruuth K, Kamaraj S, Wang C-L, Yang H-L, Combaret V, Djos A, Martinsson T, Christensen J G, Palmer R H, Hallberg B, Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells, 10.1038/onc.2012.12
  44. Medves S., Noel L. A., Montano-Almendras C. P., Albu R. I., Schoemans H., Constantinescu S. N., Demoulin J.-B., Multiple oligomerization domains of KANK1-PDGFR  are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK, 10.3324/haematol.2011.040147
Référence bibliographique Velghe, Amélie ; Van Cauwenberghe, S ; Polyansky, A A ; Chand, D ; Montano-Almendras, C P ; et. al. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.. In: Oncogene, Vol. 33, no. 20, p. 2568-76 (2014)
Permalien http://hdl.handle.net/2078.1/130115